Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Prevnar 13 and Pneumovax 23 in Healthy Adults
NCT02225587Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2014
- Primary completion
- Jul 2015
- Modality
- Split/Subunit Vaccines
01
Overview
A Phase 3 trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal infection, sponsored by Merck & Co.. Started Aug 2014; status: completed.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT02225587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02225587.